ArticleOxford medical case reports2026
Primary Burkitt lymphoma of the breast in a young north African woman: diagnostic challenge and benefit of early intensive chemotherapy.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy that rarely presents primarily in the breast. Its rapid progression and inflammatory features can mimic breast cancer or mastitis, leading to a delay in diagnosis. A 26-year-old nulliparous North African woman presented with a painful, rapidly growing breast mass that had appeared within the last four weeks. Clinical examination revealed an 8 cm mass accompanied by orange-peel skin. Imaging suggested a likely benign lesion (BI-RADS 3). However, histology showed a classic 'starry sky' pattern, a Ki-67 rate of 100% and positivity for CD20/CD10/BCL6 with negativity for BCL2/CD5/EBER. PET-CT revealed a solitary hypermetabolic lesion (SUV 32) without systemic involvement (stage IE, BL-IPI 1). Treatment with R-COPADM was initiated within 48 hours, resulting in complete remission. This case highlights that an early biopsy is essential in the presence of any atypical inflammatory breast mass, even when imaging appears reassuring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.